Biomarker Knowledge for Busy Professionals
Track the competition to monitor the biomarkers they are using in clinical trials and new IVD products.
Research biomarker trends to identify targets for new IVD and RUO products.
Understand the trends impacting personalized medicine across all therapeutic areas.
BiomarkerBase™ helps us to identify opportunities that are much closer to being ready for commercialization.Corporate Licensing Manager
You know more than I do about what my company does.Director, Translational Medicine
Your coverage of FDA tests is better than anything else I’ve seen.Research Analyst
Get Access To Actionable Biomarkers:
CURATED CLINICAL BIOMARKERS.
Keeping up to date on the clinical biomarker landscape is difficult.
Learn how BiomarkerBase™ makes it easy, with high quality data and an easy-to-use interface.
At Amplion, we see biomarkers as the key to delivering on the promise of personalized medicine. From drug research and discovery and companion diagnostic development to patient care, we understand that biomarkers will drive personalized care. We publish two products, one paid and one free:
BiomarkerBase™ Is the Complete Knowledge Base
and Alert Service For Clinical Biomarkers.
Public sources of biomarker information have the potential to provide clear opportunities for product development and clinical trial planning. The problem is that these sources are challenging to utilize, due to their limited searchability, lack of common nomenclature, and lack of interconnectivity.
Amplion solves these challenges by manually reviewing public sources that include information about biomarkers in clinical use, aggregating and annotating that information, and providing access to it through a clean and intuitive interface. We also provide an alert service that sends you an email whenever a specific biomarker target or disease is used in a new test, drug label, or clinical trial.
This allows you to maintain a comprehensive understanding of the current clinical landscape for specific molecular targets and the diseases they help to characterize.
Easy to use, the intuitive interface of BiomarkerBase™ provides a very rich source of information about:
every biomarker used in an IVD cleared or approved by FDA
every biomarker in the label of an FDA-approved drug
thousands of emerging biomarkers in clinical trials
thousands of biomarkers in Laboratory-Developed Tests (LDTs)
THE AMPLION TEAM
Co-Founder and CEO
John is passionate about accelerating basic research discoveries into healthcare advancements. John became aware of the need for a resource like BiomarkerBase during his 7 years running MitoSciences Inc. (now part of Abcam plc). Trying to identify the next targets for new monoclonal antibodies and drug screening assays was a continuing challenge, despite the availability of lots of relevant information in the public domain.
John writes actively on topics related to biomarkers and personalized medicine at our blog Biomarker Trends. John also supports the biotech industry as a board member for the Oregon Bioscience Association and the Professional Science Masters Program at Oregon State University.
Adam Carroll, Ph.D
Co-Founder and CSO
Adam’s training as a biochemist and molecular biologist, as well as his strong affinity for data science and software projects, steered him to co-found Amplion. Building a product that supports BiomakerBase™ customers deliver on the promise of precision medicine is the most meaningful way Adam is contributing the best of both his experience and interests.
Previously, Adam has worked as a Director at Bend Research, Inc. (now a division of Capsugel) where he built new technology for clients that included Pfizer and Nike. Adam was also an Assistant Adjunct Professor at the University of California San Francisco and a technician at Harvard Medical School. Adam did his PhD work at UCSF and attended Williams College.
Co-Founder and CTO
Chris is excited by the notion that the data Amplion brings to light is helping in the work to improve the human condition. Prior to co-founding Amplion Chris was the CTO of G5, helping to grow that business to over 30+M in revenue. Chris is a summa cum laude graduate of Bowdoin College.
As an enterprise software entrepreneur, Seth’s career has included co-founding a recruiting software company, and Workday, a huge success in the burgeoning SaaS enterprise software space. Seth is excited to see Amplion contribute to the realization of the promise of personalized medicine.
Corey’s single minded focus is applying big data science techniques to personalized medicine. Though he occasionally allows time to deliberate on font choices for his future “MORE DATA” knuckle tattoos. Corey has an M.S., Physics from UC Santa Cruz and a B.S. with Honors, Physics and B.S., Mathematics, University of Oregon.
Discover how BiomarkerBase™ makes it fast and easy to identify new biomarker opportunities with these resources:
BiomarkerBase™ Learning Videos
- Intro to BiomarkerBase™
- Inclusion Criteria
- Laboratory Developed Tests (LDTs)
- Watch List
Discover what information is included in BiomarkerBase™, and how we collect and organize it.
Just getting started with your account or free trial? Our User Guide will direct you to the optimal places to explore and get started.
Market Trends for Biomarker-Based IVD Tests (2003-2014)
This complimentary report covers:
- annual test releases and review periods;
- novelty of biomarkers in tests;
- biomarker panels;
- companion diagnostic test development; and,
- the companies involved in test development.
It also takes an initial look at laboratory developed tests (LDTs), with an emphasis on panel based
After you register your email address, you will be able to download the report immediately.
Biomarker Trends™ is published by Amplion as a place to keep informed about the changing biomarker landscape and to present relevant issues related to developing and commercializing biomarker-based IVD tests.
Special focus is placed on elaborating the factors that are rate-limiting to rapid clinical implementation of candidate biomarkers and describing successful approaches to test development and use.